| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca32fd2a44fd326ffd027a75a57bd13f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2010-0077 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56988
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0042 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2014-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3254337f74ff44a333b5f60139f284fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae3f81d3aae7c424272761c894c69681
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6daf050a163e5b6591ce34df2a18f03f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_480588d6a1e665cde6b0bab494f0869c |
| publicationDate |
2014-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014308755-A1 |
| titleOfInvention |
Hmgb1 and anti-hmgb1 antibodies for the prognostic of neurological disorders |
| abstract |
The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9766254-B2 |
| priorityDate |
2010-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |